FSTL1 (E4Y1F) Rabbit mAb #77561
- WB
Supporting Data
| REACTIVITY | H M R |
| SENSITIVITY | Endogenous |
| MW (kDa) | 40 |
| Source/Isotype | Rabbit IgG |
Application Key:
- WB-Western Blotting
Species Cross-Reactivity Key:
- H-Human
- M-Mouse
- R-Rat
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| Western Blotting | 1:1000 |
Storage
Protocol
Specificity / Sensitivity
FSTL1 (E4Y1F) Rabbit mAb recognizes endogenous levels of total FSTL1 protein.
Species Reactivity:
Human, Mouse, Rat
Source / Purification
Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues near the carboxy terminus of human FSTL1 protein.
Background
Follistatin-related protein 1 (FSTL1, TSC-36, or FRP) is a secreted glycoprotein that is a member of the SPARC family (1). FSTL1 modulates multiple biological processes through various signaling pathways. FSTL1 acts as an antagonist of BMP4 to regulate the TGF-β/BMP/Smad signaling cascade (2), which is required for lung, smooth muscle, and skeletal development (2-4). As a ligand of the receptor DIP2A, FSTL1 activates downstream Akt/eNOS signaling (5), which protects the heart during injury and promotes tissue regeneration during ischemia stress and cardiovascular disease progression (6,7). FSTL1 is involved in the activation of several additional signaling cascades, such as NF-κB, Erk, AMPK, and Wnt/β-Catenin pathways (8,9). By mediating these signaling pathways, FSTL1 contributes to immune inflammatory response (10), cancer progression, cancer-associated immune infiltration, and metastasis (11-13).
- Viloria, K. et al. (2016) Sci Rep 6, 37839.
- Geng, Y. et al. (2011) Proc Natl Acad Sci USA 108, 7058-63.
- Sylva, M. et al. (2011) PLoS One 6, e22616.
- Liu, X. et al. (2017) PLoS One 12, e0177899.
- Ouchi, N. et al. (2010) J Biol Chem 285, 7127-34.
- Oshima, Y. et al. (2008) Circulation 117, 3099-108.
- Wei, K. et al. (2015) Nature 525, 479-85.
- Mattiotti, A. et al. (2018) Cell Mol Life Sci 75, 2339-2354.
- Zhang, Y. et al. (2022) J Biol Chem 298, 102010.
- Chaly, Y. et al. (2014) Immunol Res 59, 266-72.
- Ogiwara, Y. et al. (2022) Cancer Lett 537, 215690.
- Kudo-Saito, C. et al. (2018) Cell Rep 24, 1790-1801.
- Du, R. et al. (2024) Gene 906, 148263.
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.